Elite Pharmaceuticals ELTP
OTC ELTP
$0.25 0.00 (-0.08%)
As of: Oct 23, 2026 · 12:45 PM EDT

Elite Pharmaceuticals (ELTP) Gains from Sales and Divestitures (2020 - 2024)

Updated

Elite Pharmaceuticals (ELTP) reported Gains from Sales and Divestitures of -$1.6 million for FY2025 (year ended Mar 31, 2025).

Analysis

Elite Pharmaceuticals (ELTP) Gains from Sales and Divestitures (2020 - 2024) Analysis & Trends

  • According to Business Quant data, Gains from Sales and Divestitures came in at -$292,807 in FY2023 and $48,463 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Elite Pharmaceuticals 244.53 Mn 126.20 Mn 13.51 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 -75,882.00
Jun 30, 2024 -45,599.00
Dec 31, 2020 6,973.00
Sep 30, 2020 3,400.00
Jun 30, 2020 38,090.00
API Access

Elite Pharmaceuticals Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ELTP&period=max&api_key=YOUR_API_KEY